KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Royalty Pharma (RPRX) Short term Debt: 2019-2025

Historic Short term Debt for Royalty Pharma (RPRX) over the last 4 years, with Sep 2025 value amounting to $380.0 million.

  • Royalty Pharma's Short term Debt fell 61.88% to $380.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $380.0 million, marking a year-over-year decrease of 61.88%. This contributed to the annual value of $997.8 million for FY2024, which is N/A change from last year.
  • Royalty Pharma's Short term Debt amounted to $380.0 million in Q3 2025, which was down 61.98% from $999.4 million recorded in Q2 2025.
  • Royalty Pharma's 5-year Short term Debt high stood at $999.4 million for Q2 2025, and its period low was $107.9 million during Q4 2021.
  • Its 3-year average for Short term Debt is $910.1 million, with a median of $998.4 million in 2023.
  • Per our database at Business Quant, Royalty Pharma's Short term Debt spiked by 824.19% in 2022 and then crashed by 61.88% in 2025.
  • Royalty Pharma's Short term Debt (Quarterly) stood at $107.9 million in 2021, then spiked by 824.19% to $997.5 million in 2022, then spiked by 761.60% to $999.4 million in 2023, then reached $997.8 million in 2024, then slumped by 61.88% to $380.0 million in 2025.
  • Its Short term Debt was $380.0 million in Q3 2025, compared to $999.4 million in Q2 2025 and $998.6 million in Q1 2025.